Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Felbinac intravenous - Guangdong Zhongke Drug Research & Development/Shijiazhuang Yiling Pharmaceutical

Next Previous
Drug Profile

Felbinac intravenous - Guangdong Zhongke Drug Research & Development/Shijiazhuang Yiling Pharmaceutical

Alternative Names: 4-Biphenylacetic acid; 4-Biphenylacetic Acid Trishydroxymettiylaminometnane; BPAA; CL-83544; Felbinac intravenous; Felbinac trometamol

Latest Information Update: 28 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shijiazhuang Yiling Pharmaceutical
  • Class Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain
  • No development reported Inflammation

Most Recent Events

  • 28 Sep 2022 Felbinac intravenous is still in phase III trials for Postoperative pain in China (IV) (NCT05297669)
  • 30 Jun 2022 Shijiazhuang Yiling Pharmaceutical completes a phase III trial in Postoperative pain in China (IV) (NCT05297669)
  • 30 Jun 2022 Shijiazhuang Yiling Pharmaceutical completes a phase-III clinical trial in Postoperative pain in China (IV) (NCT04526132)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top